Great West Life Assurance Co. Can Cuts Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Great West Life Assurance Co. Can lessened its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 46.9% in the third quarter, HoldingsChannel.com reports. The firm owned 13,636 shares of the biopharmaceutical company’s stock after selling 12,064 shares during the quarter. Great West Life Assurance Co. Can’s holdings in Amicus Therapeutics were worth $109,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in FOLD. Point72 Hong Kong Ltd purchased a new position in Amicus Therapeutics during the 2nd quarter valued at about $49,000. US Bancorp DE increased its holdings in Amicus Therapeutics by 50.9% during the 2nd quarter. US Bancorp DE now owns 4,896 shares of the biopharmaceutical company’s stock valued at $61,000 after acquiring an additional 1,651 shares in the last quarter. Meeder Asset Management Inc. purchased a new position in Amicus Therapeutics during the 2nd quarter valued at about $73,000. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. purchased a new position in Amicus Therapeutics during the 2nd quarter valued at about $122,000. Finally, Weil Company Inc. purchased a new position in Amicus Therapeutics during the 2nd quarter valued at about $125,000.

FOLD has been the subject of several recent research reports. Zacks Investment Research upgraded shares of Amicus Therapeutics from a “hold” rating to a “buy” rating and set a $9.25 target price for the company in a report on Monday. Cowen set a $31.00 target price on shares of Amicus Therapeutics and gave the company a “buy” rating in a report on Thursday, October 10th. ValuEngine upgraded shares of Amicus Therapeutics from a “hold” rating to a “buy” rating in a report on Wednesday, October 2nd. BidaskClub upgraded shares of Amicus Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday. Finally, HC Wainwright restated a “buy” rating and set a $18.00 target price on shares of Amicus Therapeutics in a report on Monday, October 14th. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $17.72.

In other news, CEO John F. Crowley sold 14,500 shares of Amicus Therapeutics stock in a transaction dated Friday, October 11th. The shares were sold at an average price of $8.01, for a total transaction of $116,145.00. Following the completion of the sale, the chief executive officer now directly owns 735,694 shares in the company, valued at $5,892,908.94. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Burke W. Whitman purchased 4,945 shares of the stock in a transaction dated Friday, August 23rd. The shares were purchased at an average price of $10.07 per share, with a total value of $49,796.15. Following the completion of the acquisition, the director now owns 21,612 shares of the company’s stock, valued at $217,632.84. The disclosure for this purchase can be found here. Insiders own 2.50% of the company’s stock.

Shares of NASDAQ FOLD opened at $8.92 on Friday. The company has a market cap of $2.26 billion, a PE ratio of -6.71 and a beta of 1.58. Amicus Therapeutics, Inc. has a 12 month low of $7.11 and a 12 month high of $14.61. The company has a debt-to-equity ratio of 0.31, a current ratio of 7.09 and a quick ratio of 6.97. The company has a 50-day simple moving average of $8.40 and a 200-day simple moving average of $10.89.

Amicus Therapeutics (NASDAQ:FOLD) last issued its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.34) EPS for the quarter, hitting analysts’ consensus estimates of ($0.34). The business had revenue of $44.13 million during the quarter, compared to the consensus estimate of $41.14 million. Amicus Therapeutics had a negative net margin of 336.41% and a negative return on equity of 66.79%. The company’s quarterly revenue was up 107.1% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.33) earnings per share. On average, analysts anticipate that Amicus Therapeutics, Inc. will post -1.38 EPS for the current year.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 for indications, including pompe disease.

Featured Article: What moving averages are used to define a golden cross?

Want to see what other hedge funds are holding FOLD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amicus Therapeutics, Inc. (NASDAQ:FOLD).

Institutional Ownership by Quarter for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.